tag head-and-neck-cancer 
Fierce Pharma
SEPTEMBER 22, 2023
Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.
XTalks
AUGUST 17, 2020
To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. chimeric receptor antigen [CAR] T cell) immune modulators (i.e.
Drug Discovery World
APRIL 17, 2023
Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The study will be conducted in two parts.
Expert insights. Personalized for you.
131 
Let's personalize your content